Nocodazole

Tubulin production inhibitor,anti-neoplastic agent CAS# 31430-18-9

Nocodazole

Catalog No. BCC3826----Order now to get a substantial discount!

Product Name & Size Price Stock
Nocodazole: 5mg $35 In Stock
Nocodazole: 10mg Please Inquire In Stock
Nocodazole: 20mg Please Inquire Please Inquire
Nocodazole: 50mg Please Inquire Please Inquire
Nocodazole: 100mg Please Inquire Please Inquire
Nocodazole: 200mg Please Inquire Please Inquire
Nocodazole: 500mg Please Inquire Please Inquire
Nocodazole: 1000mg Please Inquire Please Inquire
Related Products
  • Mc-MMAD

    Catalog No.:BCC1735
    CAS No.:1401963-15-2
  • MMAD

    Catalog No.:BCC1774
    CAS No.:203849-91-6
  • Eribulin

    Catalog No.:BCC5174
    CAS No.:253128-41-5
  • Colchicine

    Catalog No.:BCN6271
    CAS No.:64-86-8
  • Mc-MMAE

    Catalog No.:BCC5201
    CAS No.:863971-24-8

Quality Control of Nocodazole

Number of papers citing our products

Chemical structure

Nocodazole

3D structure

Chemical Properties of Nocodazole

Cas No. 31430-18-9 SDF Download SDF
PubChem ID 4122 Appearance Powder
Formula C14H11N3O3S M.Wt 301.32
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Oncodazole; R17934
Solubility DMSO : 20 mg/mL (66.37 mM; Need ultrasonic)
Chemical Name methyl N-[6-(thiophene-2-carbonyl)-1H-benzimidazol-2-yl]carbamate
SMILES COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3
Standard InChIKey KYRVNWMVYQXFEU-UHFFFAOYSA-N
Standard InChI InChI=1S/C14H11N3O3S/c1-20-14(19)17-13-15-9-5-4-8(7-10(9)16-13)12(18)11-3-2-6-21-11/h2-7H,1H3,(H2,15,16,17,19)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Nocodazole

DescriptionMicrotubule inhibitor; inhibits mitosis. Also inhibits autophagosome-lysosome fusion. Enhances homology-directed repair (HDR) efficiency 9 to 31% (depending on cell cycle phase) and increases Cas9-mediated gene editing frequencies.

Nocodazole Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Nocodazole Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Nocodazole

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.3187 mL 16.5937 mL 33.1873 mL 66.3746 mL 82.9683 mL
5 mM 0.6637 mL 3.3187 mL 6.6375 mL 13.2749 mL 16.5937 mL
10 mM 0.3319 mL 1.6594 mL 3.3187 mL 6.6375 mL 8.2968 mL
50 mM 0.0664 mL 0.3319 mL 0.6637 mL 1.3275 mL 1.6594 mL
100 mM 0.0332 mL 0.1659 mL 0.3319 mL 0.6637 mL 0.8297 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Nocodazole

Nocodazole is a reversible anti-neoplastic agent which exerts its effect in cells by interfering with the polymerization of microtubules (tubulin).

Featured Products
New Products
 

References on Nocodazole

An RNA-binding protein, RNP-1, protects microtubules from nocodazole and localizes to the leading edge during cytokinesis and cell migration in Dictyostelium cells.[Pubmed:27569394]

Acta Pharmacol Sin. 2016 Nov;37(11):1449-1457.

AIM: RNA-binding proteins are a large group of regulators (800-1000 in humans), some of which play significant roles in mRNA local translation. In this study, we analyzed the functions of the protein RNP-1, which was previously discovered in a genetic selection screen for Nocodazole suppression. METHODS: The growth rates and the microtubule networks of Dictyostelium cells were assessed with or without Nocodazole (10 mumol/L) in suspension culture. Fluorescent images of RNP-1-GFP and RFP-tubulin were captured when cells were undergoing cytokinesis, then the GFP signal intensity and distance to the nearest centrosome were analyzed by using a computer program written in Matlab((R)). The RNP-1-GFP-expresseding cells were polarized, and the time-lapse images of cells were captured when cells were chemotaxing to a cAMP source. RESULTS: Over-expression of RNP-1 rescued the growth defects caused by the microtubule-destabilizing agent Nocodazole. Over-expression of RNP-1 protected microtubules from Nocodazole treatment. In cells undergoing cytokinesis, the RNP-1 protein was localized to the polar regions of the cell cortex, and protein levels decreased proportionally as the power of the distance from the cell cortex to the nearest centrosome. In chemotactic cells, the RNP-1 protein localized to the leading edge of moving cells. Sequence analysis revealed that RNP-1 has two RNA-binding domains and is related to cytosolic poly(A)-binding proteins (PABPCs) in humans. CONCLUSION: RNP-1 has roles in protecting microtubules and in directing cortical movement during cytokinesis and cell migration in Dictyostelium cells. The sequence similarity of RNP-1 to human PABPCs suggests that PABPCs may have similar functions in mammalian cells, perhaps in regulating microtubule dynamics and functions during cortical movement in cytokinesis and cell migration.

Nocodazole treatment interrupted Brucella abortus invasion in RAW 264.7 cells, and successfully attenuated splenic proliferation with enhanced inflammatory response in mice.[Pubmed:28017899]

Microb Pathog. 2017 Feb;103:87-93.

Brucellosis is one of the most important and widespread zoonosis worldwide responsible for serious economic losses and considerable public health burden. In this study, we investigated the modulatory effect of a microtubule-inhibitor, Nocodazole, on B. abortus infection in murine macrophages and in a mouse model. Nocodazole activated macrophages and directly inhibited the growth of Brucella in a dose-dependent manner. Nocodazole increased adhesion but reduced invasion and intracellular growth of Brucella in macrophages although it did not affect co-localization of Brucella with LAMP-1. In addition, Nocodazole negatively affected actin polymerization, and weakly activated ERK and p38alpha but significantly activated JNK in non-infected cells. After subsequent infection, Nocodazole weakly inhibited activation of ERK and p38alpha. For the in vivo tests, Nocodazole -treated mice displayed elevated levels of IFN-gamma, MCP-1 and IL-10 while Brucella-infected Nocodazole -treated mice showed high levels of TNF, IFN-gamma, MCP-1, IL-10 and IL-6 as compared to controls. Furthermore, Nocodazole treatment reduced inflammation and Brucella proliferation in the spleens of mice. These findings highlight the potential use of Nocodazole for the control of brucellosis although further investigations are encouraged to validate its therapeutic use in animal hosts.

Nocodazole Induced Suicidal Death of Human Erythrocytes.[Pubmed:26824457]

Cell Physiol Biochem. 2016;38(1):379-92.

BACKGROUND: The microtubule assembly inhibitor Nocodazole has been shown to trigger caspase-independent mitotic death and caspase dependent apoptosis. Similar to apoptosis of nucleated cells, erythrocytes may undergo eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Stimulators of eryptosis include increase of cytosolic Ca2+ activity ([Ca2+]i), oxidative stress and ceramide. The present study explored, whether and how Nocodazole induces eryptosis. METHODS: Flow cytometry was employed to determine phosphatidylserine exposure at the cell surface from annexin-V-binding, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, the abundance of reactive oxygen species (ROS) from 2',7'-dichlorodihydrofluorescein (DCF) diacetate dependent fluorescence as well as ceramide surface abundance utilizing specific antibodies. Tubulin abundance was quantified by TubulinTracker Green reagent and visualized by confocal microscopy. RESULTS: A 48 hours exposure of human erythrocytes to Nocodazole (>/= 30 microg/ml) significantly increased the percentage of annexin-V-binding cells without significantly modifying average forward scatter. Nocodazole significantly increased Fluo3-fluorescence, significantly increased DCF fluorescence and significantly increased ceramide surface abundance. The effect of Nocodazole on annexin-V-binding was significantly blunted, but not abolished by removal of extracellular Ca2+ and was not modified in the presence of Caspase 3 inhibitor zVAD (1 microM). Nocodazole treatment reduced the content of total tubulin. CONCLUSIONS: Nocodazole triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect in part due to stimulation of Ca2+ entry, oxidative stress and ceramide.

Death-associated protein kinase 2 mediates nocodazole-induced apoptosis through interaction with tubulin.[Pubmed:26529546]

Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):113-8.

Death-associated protein kinase 2 (DAPK2) is a positive regulator of apoptosis. Although we recently reported that 14-3-3 proteins inhibit DAPK2 activity and its subsequent apoptotic effects via binding to DAPK2, the molecular mechanisms underlying the DAPK2-mediated apoptotic pathway remain unclear. Therefore, we attempted to further identify DAPK2-interacting proteins using pull-down assays and mass spectrometry. The microtubule beta-tubulin was identified as a novel DAPK2-binding protein in HeLa cells. Pull-down assays revealed that DAPK2 interacted with the alpha/beta-tubulin heterodimer, and that the C-terminal region of DAPK2, which differs from that of other DAPK family members, was sufficient for the association with beta-tubulin. Although the microtubule-depolymerizing agent Nocodazole induced apoptosis in HeLa cells, the level of apoptosis was significantly decreased in the DAPK2 knockdown cells. Furthermore, we found that treatment with Nocodazole resulted in an increased binding of DAPK2 to beta-tubulin. These findings indicate that DAPK2 mediates Nocodazole-induced apoptosis via binding to tubulin.

Methods in mammalian autophagy research.[Pubmed:20144757]

Cell. 2010 Feb 5;140(3):313-26.

Autophagy has been implicated in many physiological and pathological processes. Accordingly, there is a growing scientific need to accurately identify, quantify, and manipulate the process of autophagy. However, as autophagy involves dynamic and complicated processes, it is often analyzed incorrectly. In this Primer, we discuss methods to monitor autophagy and to modulate autophagic activity, with a primary focus on mammalian macroautophagy.

Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases.[Pubmed:15325591]

Int J Biochem Cell Biol. 2004 Dec;36(12):2541-50.

Large cytoplasmic inclusions called aggresomes are seen in many protein conformational diseases including Huntington's disease and Parkinson's disease. The roles of inclusions and aggresomes in these diseases are unresolved critical issues that have been vigorously debated. Two recent studies used microtubule disruption with Nocodazole to inhibit aggresome formation and observed increased toxicity of expanded polyglutamines in the context of huntingtin exon 1 and a truncated androgen receptor. Increased toxicity of expanded polyglutamines in the presence of Nocodazole was correlated with decreased protein turnover, leading the authors to conclude that aggresomes were cytoprotective and that they directly enhanced clearance of the toxic proteins. Here we show that Nocodazole has additional effects, which provide a simple alternative explanation for these previous observations. We confirmed aggresome formation in cells expressing proteins with polyalanine and polyglutamine expansions. As expected, we found a reduction in aggresome formation when microtubule function was disrupted using Nocodazole. However, in addition to this effect, Nocodazole treatment increased the proportions of cells with nuclear inclusions in PC12 cells expressing huntingtin exon 1 with 74 glutamines. This can be explained as Nocodazole inhibits autophagosome-lysosome fusion, a key step in mutant huntingtin exon 1 clearance. This effect alone can explain the previous observations with this compound in polyglutamine diseases and raises doubts about the interpretation of some of the data that have been used to argue that aggresomes protect against polyglutamine mutations.

Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro.[Pubmed:9201709]

Mol Biol Cell. 1997 Jun;8(6):973-85.

Previous studies demonstrated that nanomolar concentrations of Nocodazole can block cells in mitosis without net microtubule disassembly and resulted in the hypothesis that this block was due to a Nocodazole-induced stabilization of microtubules. We tested this hypothesis by examining the effects of nanomolar concentrations of Nocodazole on microtubule dynamic instability in interphase cells and in vitro with purified brain tubulin. Newt lung epithelial cell microtubules were visualized by video-enhanced differential interference contrast microscopy and cells were perfused with solutions of Nocodazole ranging in concentration from 4 to 400 nM. Microtubules showed a loss of the two-state behavior typical of dynamic instability as evidenced by the addition of a third state where they exhibited little net change in length (a paused state). Nocodazole perfusion also resulted in slower elongation and shortening velocities, increased catastrophe, and an overall decrease in microtubule turnover. Experiments performed on BSC-1 cells that were microinjected with rhodamine-labeled tubulin, incubated in Nocodazole for 1 h, and visualized by using low-light-level fluorescence microscopy showed similar results except that Nocodazole-treated BSC-1 cells showed a decrease in catastrophe. To gain insight into possible mechanisms responsible for changes in dynamic instability, we examined the effects of 4 nM to 12 microM Nocodazole on the assembly of purified tubulin from axoneme seeds. At both microtubule plus and minus ends, perfusion with Nocodazole resulted in a dose-dependent decrease in elongation and shortening velocities, increase in pause duration and catastrophe frequency, and decrease in rescue frequency. These effects, which result in an overall decrease in microtubule turnover after Nocodazole treatment, suggest that the mitotic block observed is due to a reduction in microtubule dynamic turnover. In addition, the in vitro results are similar to the effects of increasing concentrations of GDP-tubulin (TuD) subunits on microtubule assembly. Given that Nocodazole increases tubulin GTPase activity, we propose that Nocodazole acts by generating TuD subunits that then alter dynamic instability.

Description

Nocodazole is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl, and activates CRISPR/Cas9.

Keywords:

Nocodazole,31430-18-9,Oncodazole; R17934,Natural Products,Autophagy, buy Nocodazole , Nocodazole supplier , purchase Nocodazole , Nocodazole cost , Nocodazole manufacturer , order Nocodazole , high purity Nocodazole

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: